Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy

Launched by ERASMUS MEDICAL CENTER · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to monitor patients with a condition called ultralong-segment Barrett's esophagus, which can increase the risk of esophageal cancer. The researchers want to see how well the Endosign capsule sponge test works for this purpose. This test is a non-invasive method that could offer an easier way to keep track of patients’ health compared to traditional methods.

To participate in this study, individuals must be at least 18 years old and have ultralong-segment Barrett's esophagus. They should also be healthy enough to undergo an endoscopy, which is a procedure that allows doctors to look inside the esophagus. However, people with certain conditions, such as tumors in the throat or esophagus, or those who have had recent strokes affecting their swallowing, cannot join the trial. If eligible, participants can expect to undergo the Endosign test and help researchers learn more about the best ways to monitor Barrett's esophagus in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any participant 18 years and above, with ultralong-segment Barrett's esophagus and clinically fit for an endoscopy
• • Ability to provide informed consent
• Exclusion Criteria:
• • Individuals with a diagnosis of an oro-pharynx, esophageal or gastro-esophageal tumor (T2 staging and above), or symptoms of dysphagia
• • Esophageal varices or stricture requiring dilatation of the esophagus
• • Individuals who have had a cerebrovascular event \< 6 months prior where their swallowing has been affected
• • Patients who have had previous treatments such as Photodynamic therapy (PDT), Radiofrequency ablation (RFA) or Argon Plasma Coagulation (APC) for dysplastic Barrett's esophagus
• • Participants who are unable to provide informed consent
• • Participants under age 18 years